tradingkey.logo

Trinity Biotech PLC

TRIB
查看详细走势图
1.020USD
-0.260-20.31%
收盘 12/24, 13:00美东报价延迟15分钟
8.46M总市值
亏损市盈率 TTM

Trinity Biotech PLC

1.020
-0.260-20.31%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-20.31%

5天

+10.15%

1月

+15.25%

6月

+45.71%

今年开始到现在

+15.88%

1年

+23.26%

查看详细走势图

TradingKey Trinity Biotech PLC股票评分

单位: USD 更新时间: 2025-12-24

操作建议

Trinity Biotech PLC当前公司基本面数据相对谨慎,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名151/206位。机构持股占比非常高,中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Trinity Biotech PLC评分

相关信息

行业排名
151 / 206
全市场排名
447 / 4562
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 0 位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Trinity Biotech PLC亮点

亮点风险
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
业绩增长期
公司处于发展阶段,最新年度总收入61.55M美元
估值合理
公司最新PE估值-0.20,处于3年历史合理位
机构加仓
最新机构持股972.36K股,环比增加42.50%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值171.36K
活跃度增加
近期活跃度增加,过去20天平均换手率8.62

Trinity Biotech PLC新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Trinity Biotech PLC简介

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
公司代码TRIB
公司Trinity Biotech PLC
CEOGillard (John)
网址https://www.trinitybiotech.com/

常见问题

Trinity Biotech PLC(TRIB)的当前股价是多少?

Trinity Biotech PLC(TRIB)的当前股价是 1.020。

Trinity Biotech PLC的股票代码是什么?

Trinity Biotech PLC的股票代码是TRIB。

Trinity Biotech PLC股票的52周最高点是多少?

Trinity Biotech PLC股票的52周最高点是3.440。

Trinity Biotech PLC股票的52周最低点是多少?

Trinity Biotech PLC股票的52周最低点是0.480。

Trinity Biotech PLC的市值是多少?

Trinity Biotech PLC的市值是8.46M。

Trinity Biotech PLC的净利润是多少?

Trinity Biotech PLC的净利润为-31.79M。

现在Trinity Biotech PLC(TRIB)的股票是买入、持有还是卖出?

根据分析师评级,Trinity Biotech PLC(TRIB)的总体评级为--,目标价格为--。

Trinity Biotech PLC(TRIB)股票的每股收益(EPS TTM)是多少

Trinity Biotech PLC(TRIB)股票的每股收益(EPS TTM)是-5.137。
KeyAI